Table 1. Clinical characteristics and laboratory data for TAFRO-iMCD and iMCD-NOS patients.
| |
TAFRO-iMCD (n = 11) |
iMCD-NOS (n = 6) |
P value | |||
|---|---|---|---|---|---|---|
| Median | (range) | Median | (range) | |||
| Age (years) | 51 | (39–66) | 39.5 | (28–66) | NS | |
| Gender (male:female) | 8:3 | 4:2 | NS | |||
| Anasarca | 100% | (11/11) | 0% | (0/5) | P < 0.01 | |
| Fever | 81.8% | (9/11) | 0% | (0/6) | P < 0.01 | |
| Lymphadenopathy | 100% | (11/11) | 100 | (6/6) | NS | |
| Reticulin fibrosis | 85.7% | (6/7) | ND | NE | ||
| Plt | (x103 μL) | 41 | (14–171) | 348 | (295–473) | P < 0.01 |
| Hb | (g/dL) | 9.5 | (6.2–14.0) | 10.6 | (9.0–12.7) | NS |
| Alb | (g/dL) | 2.1 | (1.2–3.5) | 3.1 | (2.5–3.4) | P < 001 |
| CRP | (mg/dL) | 9.97 | (1.65–26.52) | 5.25 | (4.10–12.17) | NS |
| IgG | (mg/dL) | 1,672 | (1,208.8–2,611) | 5,168 | (3,947–6,750) | P < 0.01 |
| IgA | (mg/dL) | 221 | (142.7–426.6) | 617 | (420–964) | P < 0.01 |
| IgM | (mg/dL) | 71 | (37–257) | 218 | (168–365) | P < 0.01 |
| ALP | (IU/L) | 672 | (179–2,388) | 242.5 | (174–310) | P = 0.02 |
| Cr | (mg/dL) | 1.08 | (0.74–6.08) | 0.71 | (0.46–2.2) | P = 0.02 |
Anasarca: pleural fluid and ascites, Fever: >38.0 °C (100.4 °F), Plt: Blood platelet count, Hb: Hemoglobin, Alb: Albumin, CRP: C-reactive protein, IgG: Immunoglobulin G, IgA: Immunoglobulin A, IgM: Immunoglobulin M, ALP: alkaline phosphatase, Cr: creatinine, NS: not significant, NE: not evaluated, ND: no data.